Drug Trial Radar · NCT06842498
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Feb 22, 2026
Primary completion
Mar 31, 2028
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- Kyntra BioIndustry
- Sponsor type
- Industry
- First posted
- Feb 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior second-generation androgen receptor signaling inhibitor (ARSI) in any setting and no prior taxane therapy in the mCRPC setting.
Conditions
- Metastatic Castration-Resistant Prostate Cancer
Interventions
FG-3246Drug
FG-3246 will be administered per schedule specified in the arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radiographic Progression-free Survival (rPFS) By Investigator Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) CriteriaTime frame: Until radiographic progression is noted (up to approximately 25 months)
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From first dose until 28 days after last dose (up to approximately 25 months)
- Maximum Plasma Concentration (Cmax) of FG-3246, Total Anti-cluster of Differentiation 46 Antibody (CD46), and Free Monomethyl Auristatin E (MMAE)Time frame: Within each 21 day treatment cycle from Cycle 1 through 28 days post last dose (up to approximately 25 months)
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Western Regional Medical Center - City of Hope Phoenix Goodyear
Goodyear, Arizona · Recruiting
HonorHealth Research Institute
Scottsdale, Arizona · Recruiting
The University of Arizona Cancer Center - North Campus
Tucson, Arizona · Recruiting
VA Greater Los Angeles Healthcare System
Los Angeles, California · Recruiting
UCLA Clark Urology Center
Los Angeles, California · Recruiting
University of California San Francisco
San Francisco, California · Recruiting
New Haven Hospital - Yale Cancer Center
New Haven, Connecticut · Recruiting
Bioresearch Partner - Aventura
Aventura, Florida · Recruiting
Bioresearch Partner - Hialeah
Hialeah, Florida · Recruiting
Biogenix Molecular, LLC
Miami, Florida · Recruiting
Winship Cancer Institute, Emory University
Atlanta, Georgia · Recruiting
East Jefferson General Hospital Metairie
New Orleans, Louisiana · Recruiting
New Mexico Oncology Hematology Consultants, Ltd.
Albuquerque, New Mexico · Recruiting
Duke University Medical Center - Duke Cancer Center
Durham, North Carolina · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
Carolina Urologic Research Center
Myrtle Beach, South Carolina · Recruiting
Henry-Joyce Cancer Clinic
Nashville, Tennessee · Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas · Recruiting
Oncology Consultants
Houston, Texas · Recruiting
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
University of Washington Medical Center
Seattle, Washington · Recruiting
Northwest Medical Specialties, PLLC - Tacoma
Tacoma, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.